Synthesis and SAR of benzisothiazole- and indolizine-β-D- glucopyranoside inhibitors of SGLT2

ACS Medicinal Chemistry Letters

Volumn 1, Issue 1, 2010, Pages 19-23

  Zhou, Huiqiang ^a   Danger, Dana P ^a   Dock, Steven T ^a   Hawley, Lora ^a   Roller, Shane G ^a   Smith, Chari D ^a   Handlon, Anthony L ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Benzisothiazole and indolizine D glucopyranoside inhibitors; benzisothiazole C glucoside; SAR; SGLT2

Indexed keywords

BENZISOTHIAZOLE BETA DEXTRO GLUCOPYRANOSIDE INHIBITOR; BENZISOTHIAZOLE C GLUCOSIDE; BORONIC ACID DERIVATIVE; INDOLIZINE BETA DEXTRO GLUCOPYRANOSIDE INHIBITOR; PALLADIUM; PROTEIN INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CATALYST; CROSS COUPLING REACTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; IC 50; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77955672603     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml900010b     Document Type: Article

References (21)

1. Bays, H. From victim to ally: The kidney as an emerging target for the treatment of diabetes mellitus Curr. Med. Res. Opin. 2009, 25, 671-681
2. Washburn, W. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents Expert Opin. Ther. Pat. 2009, 19, 1485-1499
3. List, J. F.; Woo, V.; Morales, E.; Tang, W.; Fiedorek, F. T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes Diabetes Care 2009, 32, 650-657
4. Wilding, J. P. H.; Norwood, P.; T'joen, C.; Bastien, A.; List, J. F.; Fiedorek, F. T. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: Applicability of a novel insulin-independent treatment Diabetes Care 2009, 32, 1656-1662
5. Devenny, J.; Harvey, S.; Rooney, S.; Godonis, H.; Washburn, W.; Whaley, J.; Taylor, S.; Pelleymounter, M. A. The Effect of Dapagliflozin, a Highly Selective SGLT2 Inhibitor, on Body Weight in Diet-induced Obese Rats. Annual Scientific Meeting of the North American Association for the Study of Obesity (NAASO), New Orleans, LA, October 20-24, 2007.
6. Stearns, A. T.; Balakrishnan, A.; Tavakkolizadeh, A. Impact of Roux-en-Y gastric bypass surgery on rat intestinal glucose transport Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297, G950-G957
7. Zhou, L.; Cryan, E. V.; D'Andrea, M. R.; Belkowski, S.; Conway, B. R.; Demarest, K. T. Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1) J. Cell. Biochem. 2003, 90, 339-346
8. Banerjee, S. K.; McGaffin, K. R.; Pastor-Soler, N. M.; Ahmad, F. SGLT1 is a novel glucose transporter that is perturbed in disease states Cardiovasc. Res. 2009, 84, 111-118
9. Ehrenkranz, J. R. L.; Lewis, N. G.; Kahn, C. R.; Roth, J. Phlorizin: A review Diabetes/Metab. Res. Rev. 2005, 21, 31-38
10. Fujimori, Y.; Katsuno, K.; Nakashima, I.; Ishikawa-Takemura, Y.; Fujikura, H.; Isaji, M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models J. Pharmacol. Exp. Ther. 2008, 327, 268-276
11. Fujimori, Y.; Katsuno, K.; Ojima, K.; Nakashima, I.; Nakano, S.; Ishikawa-Takemura, Y.; Kusama, H.; Isaji, M. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats Eur. J. Pharmacol. 2009, 609, 148-154
12. Isaji, M. Sodium-glucose cotransporter inhibitors for diabetes Curr. Opin. Invest. Drugs (Thomson Sci.) 2007, 8, 285-292
13. Meng, W.; Ellsworth, B. A.; Nirschl, A. A.; McCann, P. J.; Patel, M.; Girotra, R. N.; Wu, G.; Sher, P. M.; Morrison, E. P.; Biller, S. A.; Zahler, R.; Deshpande, P. P.; Pullockaran, A.; Hagan, D. L.; Morgan, N.; Taylor, J. R.; Obermeier, M. T.; Humphreys, W. G.; Khanna, A.; Discenza, L.; Robertson, J. G.; Wang, A.; Han, S.; Wetterau, J. R.; Janovitz, E. B.; Flint, O. P.; Whaley, J. M.; Washburn, W. N. Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes J. Med. Chem. 2008, 51, 1145-1149
14. Goodwin, N. C.; Mabon, R.; Harrison, B. A.; Shadoan, M. K.; Almstead, Z. Y.; Xie, Y.; Healy, J.; Buhring, L. M.; DaCosta, C. M.; Bardenhagen, J.; Mseeh, F.; Liu, Q.; Nouraldeen, A.; Wilson, A. G. E.; Kimball, S. D.; Powell, D. R.; Rawlins, D. B. Novel l -Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes J. Med. Chem. 2009, 52, 6201-6204
15. Zhang, X.; Urbanski, M.; Patel, M.; Cox, G. G.; Zeck, R. E.; Bian, H.; Conway, B. R.; Beavers, M. P.; Rybczynski, P. J.; Demarest, K. T. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2 Bioorg. Med. Chem. Lett. 2006, 16, 1696-1701
16. Nomura, S.; Kawanishi, E.; Ueta, K. U.S. Patent 5,233,988. Chem. Abstr. 2005, 143, 387313.
17. Nomura, S.; Kawanishi, E.; Ueta, K. WO 2005/012326. Chem. Abstr. 2005, 142, 219491.
18. Xie, W.; Herbert, B.; Ma, J.; Nguyen, T. M.; Schumacher, R. WO2005/063767. Chem. Abstr. 2005, 143, 133366.
19. Li, H.; Xia, Z.; Chen, S.; Koya, K.; Ono, M.; Sun, L. Development of a Practical Synthesis of STA-5312, a Novel Indolizine Oxalylamide Microtubule Inhibitor Org. Process Res. Dev. 2007, 11, 246-250
20. Przewloka, T.; Chen, S.; Xia, Z.; Li, H.; Zhang, S.; Chimmanamada, D.; Kostik, E.; James, D.; Koya, K.; Sun, L. Application of DMF-methyl sulfate adduct in the regioselective synthesis of 3-acylated indolizines Tetrahedron Lett. 2007, 48, 5739-5742
21. Condreay, J. P.; Witherspoon, S. M.; Clay, W. C.; Kost, T. A. Transient and stable gene expression in mammalian cells transduced with a recombinant baculovirus vector Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 127-132